Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)

AtriCure (ATRC) reported $134.27 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.8%. EPS of -$0.01 for the same period compares to -$0.17 a year ago.

The reported revenue represents a surprise of +2.09% over the Zacks Consensus Estimate of $131.52 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• United States Revenue- Pain management: $20.84 million versus the three-analyst average estimate of $20.59 million. The reported number represents a year-over-year change of +27.7%.
• International Revenue- Pain management: $2.08 million versus the three-analyst average estimate of $2.77 million. The reported number represents a year-over-year change of +30.8%.
• United States Revenue- Total ablation: $63.86 million compared to the $63.41 million average estimate based on three analysts. The reported number represents a change of +10.04% year over year.
• International Revenue- Total ablation: $14.79 million compared to the $14.54 million average estimate based on three analysts. The reported number represents a change of +24.52% year over year.
• United States Revenue- Total: $109.31 million versus $106.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.5% change.
• International Revenue- Appendage management: $10.17 million compared to the $10.58 million average estimate based on three analysts. The reported number represents a change of +18.5% year over year.
• United States Revenue- Open ablation: $35.59 million compared to the $34.88 million average estimate based on three analysts. The reported number represents a change of +16.3% year over year.
• International Revenue- Open ablation: $10.85 million compared to the $9.73 million average estimate based on three analysts. The reported number represents a change of +26.1% year over year.
• United States Revenue- Minimally invasive ablation: $7.43 million versus the three-analyst average estimate of $7.94 million. The reported number represents a year-over-year change of -33.2%.
• International Revenue- Minimally invasive ablation: $1.86 million versus $2.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
• United States Revenue- Appendage management: $45.45 million versus the three-analyst average estimate of $43.06 million. The reported number represents a year-over-year change of +21.5%.
• International Revenue- Total: $24.96 million versus $25.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22% change.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned -4.02% over the past month versus the Zacks S&P 500 composite's +0.95% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could perform in line with the broader market in the near term.

(We are reissuing this article to correct a mistake. The original article, issued on October 29, 2025, should no longer be relied upon.)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research